FAM
BDTX icon

Fred Alger Management’s Black Diamond Therapeutics BDTX Stock Holding History

Fred Alger Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,617
Closed -$502K – 471
2020
Q3 		$502K Sell
16,617
-7,383
-31% -$225K ﹤0.01% 378
2020
Q2 		$1.01M Buy
24,000
+7,000
+41% +$258K ﹤0.01% 356
2020
Q1 		$424K Buy
+17,000
New +$517K ﹤0.01% 366

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fred Alger Management's BDTX Position: Q4 2020 in Review

Fred Alger Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2020, closing a stake of 16,617 shares — an estimated $502K sold.

Fred Alger Management first reported a position in BDTX in Q1 2020 and held it in 3 quarters. The position peaked at $1.01M in Q2 2020. 109 funds tracked by Wall St. Rank hold BDTX as of Q4 2020.

  • Fred Alger Management reported no remaining Black Diamond Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Fred Alger Management sold 16,617 Black Diamond Therapeutics shares in Q4 2020, an estimated $502K.
  • Fred Alger Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 3 quarters.
  • Fred Alger Management's Black Diamond Therapeutics position peaked at $1.01M in Q2 2020.
  • 109 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2020.

Based on Fred Alger Management's 13F filing for Q4 2020, filed 16 Feb 2021.